Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now full pipeline

Emphysema: full-pipeline trial registry

8 of 27 indexed Emphysema trials are currently recruiting.

Corpus placement: #598 of 28,707 conditions by registered trial count.

27 US clinical trials · 8 currently recruiting · #598 of 28,707 conditions by registered trial count

Emphysema: 27 US clinical trials tracked, 8 recruiting.

Emphysema is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Olympus Corporation of the Americas, running 2 of these trials.

Enrollment posture brief

Registry condition emphysema

OPEN 8 | RECR 30% | LATE 5 | EARLY 7 | RANK #598 | SPON 2

Nearest open-share peer: Substance-Related Disorders (30% recruiting · 64 trials)

Alopecia Areata55.6%Acute Ischemic Stroke44.4%Emphysema (this)30%Adenocarcinoma25.9%Acne22.2%
Open-enrollment share among volume-matched conditions near Emphysema

Emphysema lists 8 open slots (30% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Emphysema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Emphysema is recruiting below its size-band peers.

    8 of 27 indexed trials (29.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Emphysema trials is spread across many organizations.

    Olympus Corporation of the Americas accounts for 2 of 27 trials (7.4%). 24 distinct sponsors appear on at least one study for this condition label.

  3. Typical Emphysema enrolment sits around 150 participants.

    Median target enrolment is 150 among the 26 trials that report a genuine target (sentinel values excluded). 10 of those (38.5%) plan for fewer than 100 participants.

  4. Emphysema splits between interventional and observational designs.

    18 interventional and 9 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 32Phase 43

Open and recent trials

27 total, page 1 of 1

RECRUITING 75,000 participants

COPD Patient-Powered Research Network

COPD Foundation

NCT02803242

RECRUITING 3,000 participants

Emphysema Research Registry and Biosample Repository

University of Pittsburgh

NCT00307281

RECRUITING NA 250 participants

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

Apreo Health

NCT06891755

RECRUITING Phase 2 185 participants

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Sanofi

NCT05897424

RECRUITING 150 participants

STRIVE Post-Market Registry Study

Olympus Corporation of the Americas

NCT04302272

RECRUITING NA 80 participants

Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD

The Cleveland Clinic

NCT07059637

RECRUITING 60 participants

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Gelb, Arthur F., M.D.

NCT03263130

RECRUITING Phase 2 30 participants

Biological Effects of Quercetin in COPD Phase II

Temple University

NCT06003270

ACTIVE NOT RECRUITING 10,718 participants

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

Brigham and Women's Hospital

NCT00608764

ACTIVE NOT RECRUITING 2,981 participants

Study of COPD Subgroups and Biomarkers

University of North Carolina, Chapel Hill

NCT01969344

ACTIVE NOT RECRUITING 150 participants

Zephyr Valve Registry (ZEVR)

Pulmonx Corporation

NCT04186546

ACTIVE NOT RECRUITING Phase 2 133 participants

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

Weill Medical College of Cornell University

NCT05382208

ACTIVE NOT RECRUITING Phase 4 17 participants

Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema

Eric A. Hoffman

NCT02682147

COMPLETED Phase 3 741 participants

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Sumitomo Pharma America

NCT00064402

COMPLETED Phase 3 443 participants

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Sumitomo Pharma America

NCT00250679

COMPLETED NA 277 participants

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

Olympus Corporation of the Americas

NCT00475007

COMPLETED 255 participants

Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease

Washington University School of Medicine

NCT00725309

COMPLETED Phase 4 220 participants

Losartan Effects on Emphysema Progression

JHSPH Center for Clinical Trials

NCT02696564

COMPLETED Phase 2 118 participants

Prostaglandin Inhibition for Emphysema

University of Nebraska

NCT02006576

COMPLETED 117 participants

Alpha-1 Carrier Genomics Study

Medical University of South Carolina

NCT02810327

COMPLETED Phase 4 50 participants

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

Johns Hopkins University

NCT00181207

COMPLETED Phase 1 44 participants

Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen

Hal C Charles

NCT01710449

COMPLETED NA 24 participants

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

University of North Carolina, Chapel Hill

NCT01615484

COMPLETED Phase 1 17 participants

Real-Time Support for Exercise Persistence in COPD

University of Washington

NCT00373932

COMPLETED Phase 2 17 participants

Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies

University of Alabama at Birmingham

NCT03244059

COMPLETED NA 6 participants

A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients

Mayo Clinic

NCT03814980

COMPLETED NA

Lung Volume Reductions Surgery (LVRS) Study

US Department of Veterans Affairs

NCT00018525

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 2
Phase 4 3

Named interventions

Most-linked intervention names on Emphysema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
application on a computer tablet Device
1 trials
mindful breathing application Behavioral
1 trials
IBV® Valve System Device
1 trials
placebo pneumatic vest Other
1 trials
pneumatic vest Device
1 trials
Self-Monitored exercise persistence intervention Behavioral
1 trials
Coached exercise persistence intervention Behavioral
1 trials

US sites by state

Facility locations filed on Emphysema trials. A trial with sites in several states counts in each.

California 12 trials
Alabama 12 trials
Pennsylvania 10 trials
Colorado 8 trials
Texas 7 trials
Florida 7 trials
New York 6 trials
North Carolina 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Emphysema page

27 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Emphysema condition card totals 27 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.